Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003770486 | SCV001483505 | uncertain significance | Absence seizure; Myoclonic epilepsy, juvenile, susceptibility to, 1 | 2022-07-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 998730). This variant has not been reported in the literature in individuals affected with EFHC1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 437 of the EFHC1 protein (p.Arg437Gly). |
Ambry Genetics | RCV004035612 | SCV004862656 | uncertain significance | not specified | 2023-09-20 | criteria provided, single submitter | clinical testing | The c.1309A>G (p.R437G) alteration is located in exon 8 (coding exon 8) of the EFHC1 gene. This alteration results from a A to G substitution at nucleotide position 1309, causing the arginine (R) at amino acid position 437 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |